Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1

Yan,Rong; Li,Kang; Yuan,Da-Wei; Wang,Hao-Nan; Zhang,Yong; Dang,Cheng-Xue; Zhu,Kun

doi:10.3892/ijo.2018.4595

Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1

Authors:
- Rong Yan
- Kang Li
- Da-Wei Yuan
- Hao-Nan Wang
- Yong Zhang
- Cheng-Xue Dang
- Kun Zhu
View Affiliations

Affiliations: Department of Oncology Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: October 12, 2018 https://doi.org/10.3892/ijo.2018.4595
Pages: 2566-2578
Copyright: © Yan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is one of the leading causes of cancer-associated mortality worldwide. The aim of the present study was to investigate the mechanism of microRNA-4295 (miR-4295), which regulates cisplatin (DDP)-induced apoptosis in GC cells through the leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1)-mediated epidermal growth factor receptor (EGFR)/phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway. Two cell lines were selected, one with the highest expression of miR-4295 and one with the lowest expression of LRIG1, for the experiments. The half maximal inhibitory concentration of DDP in the human GC MKN-28 and MKN-45 cell lines was calculated, and mitochondrial membrane potentials of the GC cells were detected by tetramethylrhodamine, ethyl ester, perchlorate staining. The proliferation and apoptosis of GC cells with or without DDP treatment were assessed by MTT assay and plate colony formation, as well as flow cytometry and TUNEL staining. Western blot analysis and reverse transcription-quantitative polymerase chain reaction were employed to determine the expression of EGFR/PI3K/Akt signaling pathway-related genes and apoptosis-related genes. LRIG1 was identified as a target gene of miR-4295. The expression of miR-4295 was upregulated, and the expression of LRIG1 was downregulated in GC cells. Furthermore, DDP enhanced the decrease in miR-4295 expression and the increase in LRIG1 expression in GC cells. miR-4295 promoted the proliferation and inhibited the DDP-induced apoptosis of GC cells without DDP treatment. In addition, miR-4295 increased the expression levels of EGFR, PI3K, Akt, p-PI3K and p-Akt, suggesting that miR-4295 promotes the activation of the EGFR/PI3K/Akt signaling pathway by targeting LRIG1. miR-4295 targeted and negatively regulated LRIG1 expression to activate the EGFR/PI3K/Akt signaling pathway, thereby promoting the proliferation of the GC cells and inhibiting the apoptosis of the GC cells induced by DDP. Therefore, miR-4295 may be a novel therapeutic target in patients with GC.

View Figures

View References

1	Ang TL and Fock KM: Clinical epidemiology of gastric cancer. Singapore Med J. 55:621–628. 2014. View Article : Google Scholar
2	Song H, Ekheden IG, Zheng Z, Ericsson J, Nyrén O and Ye W: Incidence of gastric cancer among patients with gastric precancerous lesions: Observational cohort study in a low risk Western population. BMJ. 351:h38672015. View Article : Google Scholar : PubMed/NCBI
3	Chen G, Xu M, Chen J, Hong L, Lin W, Zhao S, Zhang G, Dan G and Liu S: Clinicopathological features and increased expression of toll-like receptor 4 of gastric cardia cancer in a high-risk chinese population. J Immunol Res. 2018:71328682018. View Article : Google Scholar : PubMed/NCBI
4	He J, Qi H, Chen F and Cao C: MicroRNA-25 contributes to cisplatin resistance in gastric cancer cells by inhibiting forkhead box O3a. Oncol Lett. 14:6097–6102. 2017.PubMed/NCBI
5	Silberman H: Perioperative adjunctive treatment in the management of operable gastric cancer. J Surg Oncol. 90:174–187. 2005. View Article : Google Scholar : PubMed/NCBI
6	Luo Y, Cui S, Tang F, Shen C, Qi Y, Lu D, Ma L, Yang Y, Li Y, Chen R, et al: The combination of crocin with cisplatin suppresses growth of gastric carcinoma cell line BGC-823 and promotes cell apoptosis. Pak J Pharm Sci. 30:1629–1634. 2017.PubMed/NCBI
7	Lai KW, Koh KX, Loh M, Tada K, Subramaniam MM, Lim XY, Vaithilingam A, Salto-Tellez M, Iacopetta B, Ito Y, et al: Singapore Gastric Cancer Consortium: MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer. 46:1456–1463. 2010. View Article : Google Scholar : PubMed/NCBI
8	Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang X, Jiang L, Sun Z, Miao Z and Xu H: MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene. 31:1398–1407. 2012. View Article : Google Scholar :
9	Chang L, Guo F, Wang Y, Lv Y, Huo B, Wang L and Liu W: MicroRNA-200c regulates the sensitivity of chemotherapy of gastric cancer SGC7901/DDP cells by directly targeting RhoE. Pathol Oncol Res. 20:93–98. 2014. View Article : Google Scholar
10	Nan YH, Wang J, Wang Y, Sun PH, Han YP, Fan L, Wang KC, Shen FJ and Wang WH: MiR-4295 promotes cell growth in bladder cancer by targeting BTG1. Am J Transl Res. 8:4892–4901. 2016.PubMed/NCBI
11	Shao M, Geng Y, Lu P, Xi Y, Wei S, Wang L, Fan Q and Ma W: miR-4295 promotes cell proliferation and invasion in anaplastic thyroid carcinoma via CDKN1A. Biochem Biophys Res Commun. 464:1309–1313. 2015. View Article : Google Scholar : PubMed/NCBI
12	Jiang J, Yuan Z, Sun Y, Bu Y, Li W and Fei Z: Ginsenoside Rg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of EGFR/PI3K/Akt signaling pathway. Biomed Pharmacother. 96:619–625. 2017. View Article : Google Scholar : PubMed/NCBI
13	Zhang X, Song Q, Wei C and Qu J: LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells. Cell Stress Chaperones. 20:631–641. 2015. View Article : Google Scholar : PubMed/NCBI
14	Wang B, Jiang H, Wang L, Chen X, Wu K, Zhang S, Ma S and Xia B: Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway. Oncol Lett. 13:3494–3500. 2017. View Article : Google Scholar : PubMed/NCBI
15	Han BH, Lee YJ, Yoon JJ, Choi ES, Namgung S, Jin XJ, Jeong DH, Kang DG and Lee HS: Hwangryunhaedoktang exerts anti-inflammation on LPS-induced NO production by suppressing MAPK and NF-κB activation in RAW264.7 macrophages. J Integr Med. 15:326–336. 2017. View Article : Google Scholar : PubMed/NCBI
16	Jiang Q, Wu C and Zhang Q: microRNA-34a participates in lipopolysaccharide mediated sepsis related renal function impairment via Kruppel-like factor 4. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 30:351–354. 2018.In Chinese. PubMed/NCBI
17	Mondal J, Samadder A and Khuda-Bukhsh AR: Psorinum 6x triggers apoptosis signals in human lung cancer cells. J Integr Med. 14:143–153. 2016. View Article : Google Scholar : PubMed/NCBI
18	Cimas FJ, Callejas-Valera JL, Pascual-Serra R, García-Cano J, Garcia-Gil E, De la Cruz-Morcillo MA, Ortega-Muelas M, Serrano-Oviedo L, Gutkind JS and Sánchez-Prieto R: MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells. Oncotarget. 6:44095–44107. 2015. View Article : Google Scholar : PubMed/NCBI
19	Kang Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, Hu W, Rupaimoole R, Liu T, Gharpure KM, Previs RA, Hansen JM, et al: Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. Clin Cancer Res. 22:1713–1724. 2016. View Article : Google Scholar :
20	Cortes-Sempere M, Chattopadhyay S, Rovira A, Rodriguez-Fanjul V, Belda-Iniesta C, Tapia M, Cejas P, Machado-Pinilla R, Manguan-García C, Sánchez-Pérez I, et al: MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer. Cancer Lett. 286:206–216. 2009. View Article : Google Scholar : PubMed/NCBI
21	Wang Q, Shi S, He W, Padilla MT, Zhang L, Wang X, Zhang B and Lin Y: Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition. Oncotarget. 5:1304–1314. 2014. View Article : Google Scholar : PubMed/NCBI
22	Wang X, Xiao Q, Xing X, Tian C, Zhang H, Ye F, Wan F, Wang B, Guo D and Lei T: LRIG1 enhances cisplatin sensitivity of glioma cell lines. Oncol Res. 20:205–211. 2012. View Article : Google Scholar : PubMed/NCBI
23	Cao W, Yang W, Fan R, Li H, Jiang J, Geng M, Jin Y and Wu Y: miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol. 35:1287–1295. 2014. View Article : Google Scholar
24	Cheng C, Qin Y, Zhi Q, Wang J and Qin C: Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol. 107:2620–2629. 2018. View Article : Google Scholar
25	Hu B, Zhang H, Wang Z, Zhang F, Wei H and Li L: LncRNA CCAT1/miR-130a3paxis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4. Cancer Biol Ther. 18:974–983. 2017. View Article : Google Scholar : PubMed/NCBI
26	Li N, Yang L, Wang H, Yi T, Jia X, Chen C and Xu P: MiR-130a and MiR-374a function as novel regulators of cisplatin resistance in human ovarian cancer A2780 cells. PLoS One. 10:e01288862015. View Article : Google Scholar : PubMed/NCBI
27	Li NW, Wang HJ, Yang LY, Jia XB, Chen C and Wang X: Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines. Sichuan Da Xue Xue Bao Yi Xue Ban. 44:865–870. 2013.In Chinese.
28	Łukaszewicz-Zając M, Szmitkowski M, Litman-Zawadzka A and Mroczko B: Matrix metalloproteinases and their tissue inhibitors in comparison to other inflammatory proteins in gastric cancer (GC). Cancer Invest. 34:305–312. 2016. View Article : Google Scholar : PubMed/NCBI
29	Wang H, Jiang Z, Chen H, Wu X, Xiang J and Peng J: MicroRNA-495 inhibits gastric cancer cell migration and invasion possibly via targeting high mobility group AT-Hook 2 (HMGA2). Med Sci Monit. 23:640–648. 2017. View Article : Google Scholar : PubMed/NCBI
30	Capes-Davis A, Theodosopoulos G, Atkin I, Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA, Reddel RR, et al: Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer. 127:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
31	Mraz M and Pospisilova S: MicroRNAs in chronic lymphocytic leukemia: From causality to associations and back. Expert Rev Hematol. 5:579–581. 2012. View Article : Google Scholar : PubMed/NCBI
32	Li X, Zheng J, Diao H and Liu Y: RUNX3 is down-regulated in glioma by Myc-regulated miR-4295. J Cell Mol Med. 20:518–525. 2016. View Article : Google Scholar : PubMed/NCBI
33	Choi E, Lantz TL, Vlacich G, Keeley TM, Samuelson LC, Coffey RJ, Goldenring JR and Powell AE: Lrig1⁺ gastric isthmal progenitor cells restore normal gastric lineage cells during damage recovery in adult mouse stomach. Gut. 67:1595–1605. 2018. View Article : Google Scholar
34	Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol. 11:136–146. 2010. View Article : Google Scholar
35	Miao J, Wu S, Peng Z, Tania M and Zhang C: MicroRNAs in osteosarcoma: Diagnostic and therapeutic aspects. Tumour Biol. 34:2093–2098. 2013. View Article : Google Scholar : PubMed/NCBI
36	Saikawa Y, Kubota T, Kuo TH, Kase S, Furukawa T, Tanino H, Ishibiki K and Kitajima M: Synergistic antitumor activity of mitomycin C and cisplatin against gastric cancer cells in vitro. J Surg Oncol. 54:98–102. 1993. View Article : Google Scholar : PubMed/NCBI
37	Kania J, Konturek SJ, Marlicz K, Hahn EG and Konturek PC: Expression of survivin and caspase-3 in gastric cancer. Dig Dis Sci. 48:266–271. 2003. View Article : Google Scholar : PubMed/NCBI
38	Yang M, Shan X, Zhou X, Qiu T, Zhu W, Ding Y, Shu Y and Liu P: miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anticancer Agents Med Chem. 14:884–891. 2014. View Article : Google Scholar : PubMed/NCBI
39	Duan H, Qu L and Shou C: Activation of EGFR-PI3K-AKT signaling is required for Mycoplasma hyorhinis-promoted gastric cancer cell migration. Cancer Cell Int. 14:1352014. View Article : Google Scholar : PubMed/NCBI
40	Zhang W, Tan Y and Ma H: Combined aspirin and apatinib treatment suppresses gastric cancer cell proliferation. Oncol Lett. 14:5409–5417. 2017.PubMed/NCBI
41	Luo J, Manning BD and Cantley LC: Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI